The Usefulness of Infliximab Treatment in the Acute Phase of Kawasaki Disease
Kawasaki Disease · 2024
DOI: 10.59492/kd.2024.2.1.e1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kawasaki Disease, 2024. Verfasst von Min Seob Song. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Infliximab, a tumor necrosis factor (TNF)-α blocking monoclonal antibody, is regarded as an effective and safe treatment modality for Kawasaki disease (KD). In clinical practice, infliximab administration in patients with KD has been associated with a shortened duration of fever and reduced hospital stays. Patients with KD who were treated with infliximab also showed improved outcomes in terms of resistance to intravenous immunoglobulin (IVIG) and coronary artery lesions (CALs). Many studies suggest that infliximab is beneficial not only as a second-line treatment for refractory KD but also as part of first-line intensification treatment with IVIG. Infliximab at a dose of 10 mg/kg/day appears to be more effective in treating refractory KD and reducing CALs compared to a 5 mg/kg/day dose. Although potential side effects of infliximab, such as an increased risk of infection and malignancy, are recognized, these risks appear to be lower in short-term single-use cases in KD patients compared to long-term, repeated use in patients with rheumatic or inflammatory bowel disease conditions. Further studies are required to establish the optimal dosing regimen and timing for infliximab administration, as well as to determine its long-term effects on coronary outcomes.
Zitieren
APA
Song, M. S. (2024). The Usefulness of Infliximab Treatment in the Acute Phase of Kawasaki Disease. Kawasaki Disease. https://doi.org/10.59492/kd.2024.2.1.e1
Vancouver
Song MS. The Usefulness of Infliximab Treatment in the Acute Phase of Kawasaki Disease. Kawasaki Disease. 2024. doi:10.59492/kd.2024.2.1.e1
BibTeX
@article{Song2024,
author = {Song, Min Seob},
title = {The Usefulness of Infliximab Treatment in the Acute Phase of Kawasaki Disease},
journal = {Kawasaki Disease},
year = {2024},
doi = {10.59492/kd.2024.2.1.e1}
}
EUVIMED